LL-37
Experimental Antimicrobial Peptide
LL-37 is a human cathelicidin-derived antimicrobial peptide. It is pleiotropic, can be pro-inflammatory, and has no established consumer systemic use.
Pharmacokinetic model
A route-level PK model for ll-37 is being prepared from published data. Dosing references, studies, and documented interactions are below; the app catalog is updated as models are validated.
Key facts
- Category
- Experimental Antimicrobial Peptide
- Suggested cadence
- once daily
Research behind this entry
-
Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers: A multicentric prospective randomized placebo-controlled clinical trial
A phase IIb randomized trial tested topical LL-37 with compression therapy in 148 venous-leg-ulcer patients. It does not establish systemic or injectable peptide PK.
1 published study referenced in the app, each with a plain-language summary.